Welcome to our dedicated page for MINERVA SURGICAL news (Ticker: UTRS), a resource for investors and traders seeking the latest updates and insights on MINERVA SURGICAL stock.
Minerva Surgical, Inc. (Nasdaq: UTRS) maintains this comprehensive news hub for stakeholders in women's healthcare innovation. As a leader in developing minimally invasive solutions for abnormal uterine bleeding, our resource centralizes official updates about therapeutic advancements and corporate developments.
This curated collection serves investors tracking medical device sector performance, healthcare professionals evaluating treatment options, and patients seeking cutting-edge alternatives to traditional procedures. You'll find verified information spanning product innovations, regulatory milestones, and strategic partnerships, all critical for understanding the company's market position.
Regular updates include developments related to flagship systems like Symphion and Minerva ES, financial performance summaries, and clinical study outcomes. Each release undergoes verification to ensure alignment with SEC compliance standards and medical accuracy requirements.
For consistent access to primary-source information about uterine health advancements, consider bookmarking this page or setting news alerts through your preferred financial platform. Always consult licensed professionals when making healthcare or investment decisions.
Minerva Surgical, Inc. (Nasdaq: UTRS) announced it will release its first quarter 2023 financial results on May 2, 2023. The announcement comes with a scheduled conference call and webcast at 1:30 p.m. Pacific Time to discuss the financial outcomes and recent developments. The company focuses on developing minimally invasive solutions for uterine healthcare, specifically addressing Abnormal Uterine Bleeding (AUB) while aiming to eliminate unnecessary hysterectomies. Minerva Surgical's product line is commercially available and aims to cater to various uterine anatomies, meeting the distinct needs of women's healthcare.
Minerva Surgical (Nasdaq: UTRS) appointed Kaile Zagger as its new Chief Commercial Officer. Zagger brings over 20 years of healthcare experience, including leadership roles in prominent companies such as Boston Scientific and GE Healthcare. Her experience in driving growth and productivity aligns with Minerva's mission to enhance women's healthcare. Todd Usen, CEO, expressed confidence in Zagger's ability to lead strategic growth. Zagger emphasized her commitment to improving women's health and aims to reposition the company as a leader in this critical sector. Minerva Surgical focuses on minimally invasive solutions for uterine healthcare needs.
Minerva Surgical reported its fourth quarter and full-year financial results for 2022, revealing a slight increase in quarterly revenue to $13.8 million, up from $13.6 million in Q4 2021. Full-year revenue reached $50.3 million, down 3% from 2021. The CEO Todd Usen emphasized that a $30 million private placement in February 2023 positions the company for growth. However, the company faced a net loss of $34.1 million in 2022 compared to $21.5 million in 2021, and a decrease in gross margin to 54.2%.
The company plans to discuss 2023 guidance during its Q1 earnings call in May.
Minerva Surgical, Inc. (Nasdaq: UTRS) will release its Q4 and full-year 2022 financial results on March 21, 2023. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET that same day to discuss the results and company highlights. Minerva focuses on minimally invasive solutions for Abnormal Uterine Bleeding (AUB), aiming to provide alternatives to hysterectomy and improve women's uterine healthcare. The company offers a range of products designed to address common causes of AUB, enhancing treatment options while avoiding unnecessary surgeries.
Minerva Surgical, Inc. (Nasdaq: UTRS) has successfully completed a private placement, selling 146,627,565 shares at $0.2046 each, raising approximately $30 million before expenses. Accelmed Partners led the placement, becoming the controlling stockholder. The funds will support operations, R&D, and general corporate purposes. CEO Todd Usen expressed optimism about this funding, indicating it will help the company grow and meet women's healthcare needs. The shares issued were sold under an exemption from the Securities Act and require an SEC registration for resale.
Minerva Surgical, focused on women's health and treatment of Abnormal Uterine Bleeding (AUB), will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12th at 9:45 a.m. PT. The event will be accessible via a live audio webcast on Minerva's website. The company offers minimally invasive alternatives to hysterectomy for AUB treatment, aiming to address common uterine health issues and avoid unnecessary surgeries.
Minerva Surgical (Nasdaq: UTRS) announced that CEO David Clapper will retire effective January 2, 2023, after over 11 years in leadership. Todd Usen has been appointed as his successor. The transition will include Clapper's continued involvement through a consulting agreement for 12 months to ensure stability. Under Clapper's tenure, the company secured vital financing and established itself in women's health. Usen, previously CEO of Activ Surgical, brings extensive experience in medical devices, aiming to drive growth and enhance solutions for treating Abnormal Uterine Bleeding.
FAQ
What is the current stock price of MINERVA SURGICAL (UTRS)?
What is the market cap of MINERVA SURGICAL (UTRS)?
